Project Twenty21 - Key Learnings

Missed the webcast with Professor David Nutt, Founder of Drug Science and Tejinder Virk, President of Khiron Europe?

There was lots to learn about how the two organizations are working together on Project Twenty21, Europes first and largest medical cannabis registry.

Here are some of the highlights:

  • Almost all of the 1.5 million daily (medical) cannabis uses in the UK are illegal. A legalized environment will help the country get out of the black market, offset associated crime and importantly address product quality and consistency concerns
  • Doctors in the UK lack medical cannabis education, and as a result doctor education is critical to impacting government legislation and patient adoption
  • Project Twenty21 already has over 7,000 participants and is aiming to reach 20,000 by 2020. Registration is intentionally a simple process where participation can join by visiting
  • Project Twenty21 is a registry, not a trial. Its aim is to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines for patients who would benefit from them
  • As greater access to education and training emerges, including through Project Twenty21, confidence in prescribing practices is expected to improve, especially with an evidence base that supports the medicines’ efficacy and official endorsements from organizations such as the National Institute for Health and Care Excellence (NICE)
  • The NHS is a vital service in the UK but requires education to expand on the limited UK adoption of medical cannabis. Access to medical cannabis in the NHS is currently limited to a few areas; severe treatment-resistant epilepsy, MS-related spasticity, and chemo-induced nausea and vomiting
  • The Covid-19 pandemic is accelerating interest in Project Twenty21with the rapid adoption of telehealth practices across the UK.  This is a trend being seen worldwide, including in Colombia where Khiron lis receiving high engagement from its telehealth services
  • In 2016 the UK produced 44% of the global cannabis plants intended for scientific and medicinal research
  • In November 2018 medicinal cannabis was legalized in the UK under a restrictive basis, with authorization for scripts to be issued only from the country’s 80,000 doctors under the GMC special register
  • As bulk imports to the UK increase, so too will patient access, driving down the cost of medicines to patients and the NHS, improving stability of access, while facilitating an exponential growth in patient numbers
  • It is estimated that up to 1% of the UK population could be medical cannabis patients by 2028
  • Khiron is the exclusive LatAm provider of medical cannabis to Project Twenty21, and has received first participant scripts
Professor David Nutt is a world renowned neuroscientist, leading global authority on drug policy reform and former chief drug advisor to the UK government. He serves as the Edmond J. Safra Professor of Neuropsychopharmacology and director of the neuropsychopharmacology unit in the Division of Brain Sciences at Imperial College London, and Founding Chair of Drug Science (formerly the Independent Scientific Committee on Drugs). Professor Nutt is the founder of Drug Science, the leading independent scientific body on drugs in the UK. 
View the full webcast recording to see how Khiron sand Project Twenty 21 are working to help UK patients better access medical cannabis.